First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this ...

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma ...

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma pa ...

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this month at Frankston Hospital ...

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this month at Frankston Hospital, VictoriaFurther site to follow at Curie Oncology, ...

Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help ...